About Careers Internship MedBlog Contact us

Ovarian Cancer Patients' Survival Time Increased With Experimental Drug

by Venkatraman on September 28, 2007 at 6:47 PM
Ovarian Cancer Patients' Survival Time Increased With Experimental Drug

An experimental drug called pertuzumab may help prolong the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor has said.

Dr. Sharmila Makhija, an associate professor in the Division of Gynecologic Oncology at the university, said that Phase II clinical trial data showed that pertuzumab added weeks to the lives of Stage III ovarian cancer patients, whose disease had returned after treatment with the existing chemotherapy regimens.


She revealed that during the study, pertuzumab was administered in combination with a standard chemotherapy agent after the initial treatments had been given, and after the re-emergence of cancer.

The researcher said that the new combination added weeks to the standard survival period for recurrent patients, and the drug combo caused minimal side effects.

"We wanted to know if pertuzumab would improve the effects of the chemotherapy with cancer recurrence, and if it would improve their lives. It did. Now we want to see if it impacts overall survival," Makhija said.

She said the Phase 2 study on 130 women had been closed, and that the researchers were planning a larger Phase 3 study of pertuzumab, which would include hundreds of US women.

The study was presented at a scientific session of the 14th European Cancer Conference in Barcelona, Spain.

Source: ANI
Font : A-A+



Recommended Readings

Latest Cancer News

Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
Novel Photo-Oxidation Therapy Holds Promise for Anticancer Treatment
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 Genes Linked to Aggressive Prostate Cancer
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
Painless Lumps in the Body May Signal Lymphatic Cancer Risk
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Ovarian Cancer Patients' Survival Time Increased With Experimental Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests